Navigation Links
Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
Date:9/15/2009

SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

(Logo:http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

"The additional data highlight fidaxomicin's unique profile as a new antibiotic class with beneficial characteristics for treating CDI," said Michael N. Chang, Ph.D., President and CEO of Optimer Pharmaceuticals. "These analyses describe fidaxomicin's low recurrence rate, safety profile, potent activity against CDI, and minimal disruption to the normal intestinal flora. We think fidaxomicin has the potential to be the treatment of choice for CDI which is a serious unmet medical need with limited treatment options."

Yoav Golan, M.D., an investigator from the Tufts Medical Center in Boston, MA, presented additional analyses around the previously reported recurrence data showing that patients treated with fidaxomicin had a substantially lower recurrence rate (13.3%) than those treated with vancomycin (24.0%). However, the recurrence rate difference between fidaxomicin and vancomycin was even greater, 10.9% versus 24.3%, respectively, in patients who did not receive CDI therapy (either vancomycin or metronidazole) in the 24-hour pre-trial enrollment period. Dr. Golan further noted that CDI recurrence occurred significantly later in patients t
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... N.J., Dec. 16 Ethicon, Inc., a ... company and a worldwide leader in surgical care, ... company dedicated to designing, developing and commercializing devices ... throat (ENT), today announced a definitive merger agreement ... transaction for approximately $785 million net of estimated ...
(Date:12/16/2009)... LAKE FOREST, Ill., Dec. 16 Hospira, Inc. ... pharmaceutical and medication delivery company, today announced that it ... and full-year 2009 results and projections for 2010 on ... ,, The company will release its fourth-quarter and full-year ... market open and the conference call. ,, A live ...
(Date:12/16/2009)... 16 International, well-known,scientific experts ... GFT505 (80 mg/day),data presented as "extremely ... scientists and clinicians critically reviewed these ... of generic lipid-modifying,treatments, fenofibrate and bezafibrate, ... observed in patients with metabolic syndrome,and ...
Breaking Medicine Technology:Ethicon Announces Definitive Agreement to Acquire Acclarent 2Ethicon Announces Definitive Agreement to Acquire Acclarent 3Ethicon Announces Definitive Agreement to Acquire Acclarent 4International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 2International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 3Pitt researchers harness carbon nanomaterials for drug delivery systems oxygen sensors 54668 1Pitt researchers harness carbon nanomaterials for drug delivery systems oxygen sensors 54668 2American Lung Association in Florida Joins Anti Recession Campaign by Forming Strategic Alliance With www i am anti recession com 54664 1American Lung Association in Florida Joins Anti Recession Campaign by Forming Strategic Alliance With www i am anti recession com 54664 2Study shows how to boost value of Alzheimers fighting compounds 54660 1Study shows how to boost value of Alzheimers fighting compounds 54660 2
... University graduate student has found a correlation between childhood obesity ... doctoral student in human nutrition, Manhattan, conducted research that found that ... of physical activity had greater amounts of airway narrowing after exercise. ... and inactive are having -- even at the age of 8 ...
... LONDON, Dec. 11 On December 11, 2008, ... and Drug Administration (FDA) - including the Drug ... Advisory Committee, and the Pulmonary-Allergy Drugs Advisory Committee ... risks of asthma medications containing long-acting beta-agonists (LABAs). ...
Other Medicine Technology:K-State Researcher Finds Correlation Between Childhood Obesity and Asthma 2K-State Researcher Finds Correlation Between Childhood Obesity and Asthma 3AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R) 2AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R) 3AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R) 4
(Date:12/16/2009)... If proposed health care legislation is enacted, it ... system. Approximately 18.4 million Californians and 161 million ... employer-based insurance for their health care coverage. ... legislation entail specific requirements for employer-based insurance. ... firms that currently comply with most new standards, ...
(Date:12/16/2009)... Raises Significant Funds to Benefit of Children with Autism ... Taylor, Gary Cole and Zachary Levi Join Ben Stiller ... ANGELES, Dec. 16 At its 13th annual ... individuals. Hasbro President & CEO Brian ... in recognition of his far-reaching philanthropic leadership and commitment ...
(Date:12/16/2009)... -- Immucor, Inc. (Nasdaq: BLUD ), a global ... transfusion industry, today announced that Paul D. Mintz, M.D. ... independent director, effective January 1, 2010. ,, Dr. ... medicine for more than 30 years. He is a ... of Virginia School of Medicine. He also serves as ...
(Date:12/16/2009)... The most widely used human embryonic stem cell ... justice questions that must be addressed to ensure that ... according to a University of Michigan research team. ,, ... U-M team analyzed 47 embryonic stem cell lines, including ... researchers. The scientists determined the genetic ancestry of each ...
(Date:12/16/2009)... Scientists pinpoint seven that increase susceptibility to disease ... genes associated with increased susceptibility to leprosy have ... , The researchers, who analyzed more than 10,000 ... in China, said their discovery highlights the important ... the development of leprosy. , "Though leprosy is ...
Breaking Medicine News(10 mins):Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 2Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 3Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 2Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 3Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 4Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 5Health News:Immucor Appoints New Board Director 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 3Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 4Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 5Health News:Leprosy Genes Identified 2
... by Avalere Health found that nearly 30% of long-term ... higher than amounts reported in widely used previous estimates. ... assisted living, a key component of long-term care.This analysis, ... that individuals and their families contributed an estimated $64 ...
... Bio-Optronics, Inc., a leader in healthcare workflow ... solution, the only comprehensive, flexible, and easy-to-use patient ... capability.The Joint Commission,s #1 patient safety goal is ... ID bands are difficult to read and time-consuming ...
... Philadelphia, 5 March 2009 The new medical subspecialty ... the way in providing technically advanced yet cost-effective care ... in the March issue of the Journal of ... the Heart Failure Society of America (HFSA) and the ...
... Connecticut,s Largest Home Care Agencies Automates and Connects ... 5 Allscripts announced today that VNA HealthCare, ... Homecare as its electronic home care system. VNA ... independent living services to 60 communities in the ...
... only specialized clinic furthers AED industry-leading commitment to ... 67th annual meeting of the American Academy of ... Inc. (Nasdaq: SLTM ) today announced ... to advance the company,s new product development, facilitate ...
... United States and Canadian Academy of Pathology (USCAP)SUNNYVALE, ... the Elekta Group and leading provider of software ... the introduction of PowerPath version 9.3, including new ... at USCAP conference in Boston, March 9-11, 2009. ...
Other Medicine News:Health News:Almost 30% of Long-Term Care is Financed Out-of-Pocket, Report Finds 2Health News:bioPoint(TM) PID Wristband Software Improves Patient Identification Accuracy and Safety 2Health News:New specialty to focus on advanced heart failure and heart transplantation 2Health News:VNA HealthCare Selects Allscripts Homecare 2Health News:VNA HealthCare Selects Allscripts Homecare 3Health News:VNA HealthCare Selects Allscripts Homecare 4Health News:VNA HealthCare Selects Allscripts Homecare 5Health News:Solta Medical, Inc. Announces State-of-the-Art Aesthetic Center 2Health News:Solta Medical, Inc. Announces State-of-the-Art Aesthetic Center 3Health News:Impac Software Introduces PowerPath(R) Version 9.3 AT USCAP 2Health News:Impac Software Introduces PowerPath(R) Version 9.3 AT USCAP 3
MDI will work with your facility to determine the best interim lab to fit your needs and your site....
... Type 300 ,Oblique 45, ,Type 330 ... illumination by setting the illumination between ... be ideal for use in ophthalmology ... other conventional compact microscope can; an ...
... is exactly the same as the model SP-8800 with ... separate Pachy mode. This mode has its own fixation ... all directions. It allows you to select an area ... has built-in software to calculate averages of multiple readings ...
... MedCath is the largest and most experienced ... networks in the United States. Mobile laboratories ... a daily basis, from one hospital to ... geographic area. Each mobile laboratory is fully ...
Medicine Products: